Figures computed from official regulatory filings — .
Analysttarget 25.5 USD (+1317%) · consensus 5/5 · 1 buy · 0 hold · 0 sell
Ownershipinsiders 4.15% · institutions 2.88% · short 10.4% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Aptevo Therapeutics Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia. The company also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for the treatment malignant pleural mesothelioma, non-small cell lung, gastric/gastro-esophageal, head and neck squamous cell carcinoma, pancreatic, renal, ovarian, prostate, breast, cervical, colorectal, endometrial, and bladder cancers; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate to treat multiple solid tumors; APVO442, a preclinical bispecific candidate based on the ADAPTIR-FLEX platform technology for the treatment of multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate to treat prostate cancer. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
40 buys18 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| White Marvin Ltrack record | Other | $1.7K | SEC |
| Taylor Daphne L | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Huebner Dirk | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Taylor Daphne L | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Harsanyi Zsolt | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Niederhuber John | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Huebner Dirk | Other | $634.9 | SEC |
| Abdun-Nabi Daniel | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Harsanyi Zsolt | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Kwon SoYoung | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Kunz Barbara Lopez | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Huebner Dirk | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Niederhuber John | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Lamothe Jeffrey G. | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Grant Grady III | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Kwon SoYoung | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Lamothe Jeffrey G. | Exercise | n/a (No price was disclosed in the filing) | SEC |
| White Marvin Ltrack record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| White Marvin Ltrack record | Exercise | n/a (No price was disclosed in the filing) | SEC |
| White Marvin Ltrack record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Grant Grady III | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Abdun-Nabi Daniel | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Kunz Barbara Lopez | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| White Marvin Ltrack record | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Grant Grady III | Buy | $20.1K | conv 85First in 12mo | SEC |